Head of Investor Relations
Regeneron Pharmaceuticals, Inc. (REGN)Equibles does not estimate personal net worth.
Get an email with a short summary when Regeneron Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get REGN alertsRyan Crowe is recorded as Head of Investor Relations at Regeneron Pharmaceuticals, Inc. (REGN). Ryan Crowe has spoken on 18 earnings calls and 5 other investor events across 1 company, most recently for Regeneron Pharmaceuticals, Inc. on October 30, 2026. Regeneron Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Regeneron Pharmaceuticals, Inc. includes George D. Yancopoulos, M.D., Ph.D. (Chairman), Leonard S. Schleifer, M.D., Ph.D. (Chairman), Joseph J. LaRosa (General Counsel) and 7 others.
“Thank you for your interest in Regeneron, and welcome to our third quarter 2026 earnings conference call. An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after our call concludes.”
“Well, good morning, good afternoon, and good evening to everyone listening around the world. Thank you for joining today's call to announce the expansion of the collaboration between Regeneron and Sanofi.”
“Always a pleasure to be here at the Morgan Family Healthcare Conference. I have a quick disclaimer to read as well, and then we'll get started.”
“Maybe I'll start and I'll let Marian certainly jump in. I'm sure she'll have some thoughts on this. But honestly, it comes back to the pipeline.”
“Thank you for your interest in Regenron, and welcome to our second quarter 2026 earnings conference call. An archive and transcript of this call will be available on the Regenron Investor Relations website shortly after our call concludes.”
Biotechnology · Healthcare
Head of Investor Relations
